DMU launches a pioneering online course developed and delivered by industry
8 March 2011
A pioneering new course developed and delivered by experts in industry and aimed at professionals working in the pharmaceutical and healthcare sectors, is being launched at De Montfort University Leicester (DMU).
The online Quality by Design (QbD) course is an innovative work-based learning programme being taught by experts from leading pharmaceutical and healthcare companies including AstraZeneca, Pfizer, GlaxoSmithKline and Bristol-Myers Squibb, and supported by the Pharmaceutical Technologies Research Group at DMU.
‘Quality by design’ is a scientific approach which has been developed to advance product and process quality in industry.
The new course is suitable for professionals working in pharmaceutical companies, contract manufacturing and consumer health.
It will allow them to gain the knowledge, skills and experience in this rapidly developing area of pharmaceutical development and manufacturing. It will also provide the tools and techniques to start using a ‘quality by design’ approach.
A free industry event to launch the course is being held at DMU on 15 March from 4:30pm.
Keynote speeches will be delivered by: Mike Hannay, medicines development vice-president at AstraZeneca; Martin Owen, API quality by design leader specialising in understanding uncertainty at GlaxoSmithKline and Roger Weaver; research fellow, co-development right first time program office at Pfizer.
The event will provide a unique opportunity to learn more about the course and network with senior people in the pharmaceutical industry.
To find out more information about the course or to book a place at the event visit www.dmu.ac.uk/qbd
Walkiria Schlindwein, QbD module leader at DMU, said: “This innovative course is specifically designed to be flexible for businesses and can be studied in its entirety or as separate modules. Expert practitioners from 14 companies and consultancies are involved in the course and all have hands-on ‘quality by design’ experience.”
Mike Hannay, from AstraZeneca, said: “‘Quality by design’ is at the very heart of leading-edge pharmaceutical development. The development of such a high quality course, delivered through an innovative medium, will significantly help today’s and tomorrow’s scientists build their capabilities in delivering high quality innovative medicines for patients.”
Martin Owen, from GlaxoSmithKline, said: “De Montfort University’s programme is a bold vision of collaborative creativity – bringing together a decentralised group of industrialists, consultants and academics to form a powerful crowd to drive a holistic understanding of ‘quality by design’.”
Vince McCurdy, from Pfizer, said: “This course is a unique integration of current knowledge on ‘quality by design’ from a group of leading experts in the pharmaceutical industry. The course will be an excellent training opportunity for those less familiar with ‘quality by design’ and provide those more experienced, suggestions on how to enhance their program.”
For more information please contact the De Montfort University on 0116 257 7400 or firstname.lastname@example.org Web: www.dmu.ac.uk